Electra City Tower
58 Harakevet St.
Tel Aviv
6777016
Hagit Ross
Hagit is a partner in the Capital Markets Department, specializes in securities law, corporate finance, and commercial transactions. Hagit regularly advises some of the largest and leading public companies in Israel on these topics.
Hagit possesses over 15 years of experience providing legal counsel. Her clients include public companies, companies subject to the reporting requirements of the Israel Securities Authority, boards of directors, and CEOs.
Hagit also advises companies on capital raising issues, including with respect to the publication of prospectuses and the issuance of bonds; board and committee meetings; purchase offers; compensation, options, and internal enforcement plans; shareholders’ agreements; the purchase and sale of shares; and commercial matters.
Prior to joining Barnea, Hagit worked in several leading Israeli law firms. In addition, she served as a teaching assistant at the Ramat Gan Academic Center Law School and at the College of Management.
Hagit is a member of the Securities and Capital Markets Committee of the Israeli Bar.
Education:
Ramat Gan Academic Center, LL.B, magna cum laude, 2000
Admission:
Member of Israel Bar Association since 2001
News and updates - Hagit Ross:
SPAC: A Dream Worth Half a Billion Shekels
In recent months, the IPO market has reached a boil. It seems anyone with any kind of business is dreaming about joining the Israeli stock market.
Lets look at the figures. From 2008 (the outbreak of the subprime crisis) through 2019, 76 new companies entered the Israeli stock market through an IPO process (an average of approximately 6.33 companies per year). In 2020 alone, 27 new companies entered the Israeli stock market, and in January 2021, seven new companies entered the Israeli stock market*.
The thing is, that this seems to be just the beginning.
In light of this wave of IPOs, the Israel Securities Authority is currently drafting rules to enable the launch of an IPO in Israel through a special purpose acquisition company (SPAC).
This is the latest superhot trend in the United States poised to “immigrate to Israel.” Under this model, a company without any business activity can launch an IPO to recruit capital in order to find a suitable business to acquire or merge with the SPAC within a predefined period.
During 2020, about 250 SPACs launched IPOs in the United States and raised approximately USD 80 billion.
The proposed outline for Israeli SPACs provides for an alternative to the "standard" prospectus route (publishing a prospectus requires a significant undertaking of time and money on the part of the issuing company, and requires such a company to devote considerable managerial attention). Rather, the SPAC may merely submit documents to the ISA and the Tel Aviv Stock Exchange (TASE).
The SPAC must acquire or merge an existing business into it within a predefined period (currently a period to probably be in the range of 18 to 24 months after the IPO date). Acquiring the business will be subject to the approval of the company's shareholders by a super majority. Insofar as the SPAC does not succeed in acquiring a business within the defined period, the invested funds will be returned to investors.
The initial capital raise required is between NIS 300 million and NIS 500 million. The entrepreneur itself is required to invest at least 10% of this sum, while its shares will be subject to a defined lock-up period, during which time it may not sell them. (It is reasonable to assume the lock-up period will be longer than the period currently applicable to "interested parties" in a new company, and that it will also continue for some time after the new business is added to the SPAC.)
As stated, the ISA and TASE are still hammering out the conditions for fundraising through SPACs. These conditions will most probably include ways to protect investments until the business is added (an escrow mechanism and/or investment rules), obligatory disclosures by the SPAC for the purposes of the IPO and until a business is added, the entrepreneur’s ability to draw a salary and/or management fee from the SPAC during the period prior to the acquisition of a business, and more. It is reasonable to assume a SPAC’s success in launching an IPO will rely, primarily, on the entrepreneur’s reputation. This may also help open a window for the entry of unicorn companies (high-tech companies valued at more than USD 1 billion) into the Israeli stock market.
Either way, this is an extremely interesting regulatory development, and one that will most probably have a real impact on the Israeli capital market.
*According to data on the TASE website.
ISA: Expanding Disclosure on Independent Committees
The Israel Securities Authority will soon require public companies to disclose details about independent committees tasked with overseeing transactions with controlling shareholders. The staff position was put together due to the increased need for supervision and oversight of decision-making processes in transactions between public companies and their controlling shareholders.
Barnea Represented Canomed in Issuing a Series of Options
Hagit Ross, a partner in our Capital Markets Department, represented Canomed, a company engaged in the cultivation, marketing, and direct sale of medical cannabis, in the issuance of two options series. The issuance is expected to reach a value of NIS 6 million. Canomed is one of the first companies to promote the purchase of pharmacies licensed to sell medical cannabis, thus providing the company direct access to the end consumer. Canomed itself already owns several such pharmacies.